Glucophage
(Metformin)ApprovedSmall molecule
EMD SeronoMetformin is used to treat type 2 diabetes by helping your body control blood sugar levels. It works by reducing the amount of sugar your liver produces and helping your body use insulin more effectively.[2] Glucophage is currently approved and in use across 245 indications[4].[1]
Glucophage is one of 3740 small molecule programs targeting Insulin resistance. It is currently in Approved.
245
Indications
1,420
Total Trials
18
Active Trials
3,739
Competitors
6
FDA Applications
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 242 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Glucophage
EMD SeronoApproved
Trodelvy
GileadPreclinical
Tykerb
GSKPreclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
MS Contin
Merck & Co.Preclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tricor
JJagotec
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes34 trials
Show 31 more trials
Type 2 Diabetes Mellitus21 trials
Show 18 more trials
The Effect of Metformin Treatment on Thyroid Hormone Metabolism in Euthyroid Patients With Type 2 Diabetes Mellitus
Completed·—·Phase 4·NCT00463502
Metformin21 trials
Platelet Rich Fibrin With 1% Metformin Gel for Treatment of Intrabony Defects
Completed·GGovernment Dental College and Research Institute, Bangalore·Phase 2·NCT02283554·120 enrolled
Show 18 more trials
Vaginal Administration of Metformin in PCOS Patients.
Unknown status·—·Phase 1·NCT02026869·200 enrolled
Metformin in Longevity Study (MILES).
Completed·—·Phase 4·NCT02432287·16 enrolled
Polycystic Ovary Syndrome9 trials
Evaluation of the Effects of Diosmin/Hespiridin Combination on the Clinical Outcomes in Patients With Polycystic Ovary Syndrome
Unknown status·—·Phase 4·NCT06083935·120 enrolled
Show 6 more trials
Efficacy of Metformin in Lean Women With Polycystic Ovary Syndrome
Unknown status·—·N/A·NCT00319293·20 enrolled
Interaction8 trials
Show 5 more trials
78 more indications
Gestational Diabetes5 trials
Show 2 more trials
MeDiGes Study: Metformine Use in Gestational Diabetes
Unknown status·FFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud·Phase 3·NCT04222348·200 enrolled
Insulin resistance5 trials
Insulin Resistance and Metformin Use on Volume of Benign Thyroid Nodules
Completed·—·N/A·NCT03183752·28 enrolled
Show 2 more trials
Effect of Life Style Modification and Metformin on Hypothyroidism With Insulin Resistance
Unknown status·—·Phase 4·NCT06096454·100 enrolled
Osteoarthritis3 trials
PreDiabetes3 trials
Diabetes Mellitus3 trials
Metformin as Adjuvant to Insulin Therapy in Insulin-resistant Diabetes Mellitus With Pregnancy
Completed·—·Phase 3·NCT01915550·90 enrolled
Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT05262257·120 enrolled
Empagliflozin3 trials
Coronary Artery Disease2 trials
Beta-cell Function2 trials
Safety and Efficacy2 trials
Lymphoma2 trials
Breast Cancer2 trials
Study of Erlotinib and Metformin in Triple Negative Breast Cancer
Completed·—·Phase 1·NCT01650506·8 enrolled
Drug Interactions2 trials
Heart Failure2 trials
Pregnancy2 trials
Type 2 Diabetic Patients2 trials
GLP-12 trials
Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion
Completed·—·Phase 1·NCT02749032·24 enrolled
Glaucoma2 trials
Polycystic Ovarian Syndrome2 trials
Schizophrenia1 trial
Randomized Controlled Trial1 trial
Pulmonary Arterial Hypertension1 trial
Fasting Conditions1 trial
Atrial Fibrillation1 trial
METFORMIN FOR ATRIAL FIBRILLATION
Unknown status·—·Phase 2·NCT05878535·770 enrolled
Cerebral Palsy1 trial
Diabetes1 trial
Overweight or Obese1 trial
Renal Failure1 trial
May Metformin be Used in Renal Failure?
Completed·—·Phase 2·NCT02710448·82 enrolled
Metastatic Prostate Cancer1 trial
Overweight1 trial
Weight loss1 trial
Fragile X Syndrome1 trial
Metformin in Children With Fragile X Syndrome
Recruiting·—·Phase 4·NCT05120505·20 enrolled
Type 1 Diabetes Mellitus1 trial
Adolescent1 trial
Coronary Artery Bypass1 trial
Prostate Cancer1 trial
Female1 trial
Preeclampsia1 trial
Metformin and Esomeprazole in Treatment of Early Onset Preeclampsia
Unknown status·—·N/A·NCT03717701·120 enrolled
Colorectal Cancer1 trial
Atherosclerotic Plaque1 trial
Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque
Completed·—·N/A·NCT00636766·300 enrolled
Hypogonadism1 trial
Testosterone, Metformin, or Both, for Hypogonadism in Obese Males
Completed·FFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud·Phase 3·NCT02514629·107 enrolled
Cardiovascular1 trial
Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)
Unknown status·—··NCT03627039·20,000 enrolled
Head and Neck Squamous Cell Carcinoma1 trial
Chronic Periodontitis1 trial
Locally Delivered Metformin and Aloe Vera for Treatment of Intrabody Defects in Chronic Periodontitis
Completed·GGovernment Dental College and Research Institute, Bangalore·Phase 2/3·NCT03204071·90 enrolled
Obese Patients1 trial
Randomized1 trial
Phase 11 trial
Wound Healing1 trial
Fatty Liver1 trial
Anti-diabetic Drugs and Fatty Liver Management
Unknown status·—·N/A·NCT05041673·120 enrolled
Locally-advanced Rectal Cancer1 trial
Solid Tumor1 trial
Arthritis1 trial
Hepatitis1 trial
Double-blind1 trial
Hyperglycemia1 trial
Unspecified2 trials
Regulatory
FDA Approval Timeline[5]
Nov 5, 1998
GLUCOPHAGE
NDA NDA020357
Oct 13, 2000
GLUCOPHAGE XR
NDA NDA021202
Sep 11, 2003
RIOMET
NDA NDA021591
Apr 27, 2004
FORTAMET
NDA NDA021574
Jun 3, 2005
GLUMETZA
NDA NDA021748
Aug 29, 2019
RIOMET ER
NDA NDA212595
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Glucophage drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Metformin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Mitochondrial Complex I (NADH Dehydrogenase) Inhibitor; Mitochondrial Glycerol-3-Phosphate Dehydrogenase Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
Patent Landscape[6]
Patent Cliff
May 1, 2035
Earliest patent expiration — generic entry possible after this date
Patent #Expires
9962336May 1, 2035